The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,583,578 in first-year total cost, median $2,249,470.
Most frequent study sections
- Special Emphasis Panel[ZDA1 JXR-D (04)]2
- Special Emphasis Panel[ZDA1 JXR-D (08)]1
Most frequent institutions
- INTERVEXION THERAPEUTICS, LLC1
- SELECTA BIOSCIENCES, INC.1
- VIRGINIA POLYTECHNIC INST AND ST UNIV1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | A Methamphetamine Conjugate Vaccine: From Manufacturing to IND1U01DA035511-01 | OWENS, SAMUEL MICHAELSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $3,606,802 | ZDA1 |
| 2014 | Preclinical Development and Clinical Proof of Concept of a Synthetic Nanoparticle1U01DA037592-01 | JOHNSTON, LLOYD PATRICK | SELECTA BIOSCIENCES, INC., MA | $2,249,470 | ZDA1 |
| 2014 | Novel Nanovaccines Against Nicotine Addiction1U01DA036850-01 | ZHANG, CHENMING M | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $727,306 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.